Best Peptides for Testosterone in 2026
Low testosterone, or hypogonadism, is a medical condition diagnosed and managed with a doctor, and this page is education, not a treatment plan. For each peptide studied for its effect on testosterone through the hypothalamic-pituitary-gonadal axis, it reports the trials behind it: who was enrolled, what was measured, what the paper found. Every citation was retrieved through NCBI E-utilities on 9 August 2026. The theme these studies share is signalling the body to make its own testosterone rather than supplying it from outside, and the population column is where each result is pinned to the people it came from.
6
Healthy men in the kisspeptin-54 crossover (PMID 16174713)
13
Healthy men in the kisspeptin-10 bolus study (PMID 21470997)
54
Men in the pulsatile GnRH pump cohort (PMID 40800099)
The Studies
One row per study, not one per compound. Read the population and design columns before the result, because a hormone change over 90 minutes in a healthy volunteer and a testosterone change over two years in a man with a diagnosed condition are different kinds of evidence. Rows marked as selective estrogen receptor modulators in the compound column are small molecules rather than peptides, included here as comparators on the same axis.
| Compound | Population (n) | What was measured | Result | Design | PMID |
|---|---|---|---|---|---|
| Kisspeptin-54 | 6 healthy male volunteers | Plasma LH, FSH and testosterone during a 90-minute infusion versus saline | Mean 180-minute testosterone 24.9 versus 21.7 nmol/L on saline; mean 90-minute LH 10.8 versus 4.2 U/L (both P below .001) | Double-blind placebo-controlled crossover, intravenous infusion | 16174713 |
| Kisspeptin-10 | Healthy men, 6 in the bolus arm and 4 in the infusion arm | Serum LH, LH pulse frequency and testosterone across intravenous boluses and a 22.5-hour infusion | Testosterone rose from 16.6 to 24.0 nmol/L (P below .001), alongside a rise in LH from 5.4 to 20.8 IU/L and in LH pulse frequency from 0.7 to 1.0 pulses per hour | Dose-response study, intravenous bolus and infusion, healthy men | 21632807 |
| Kisspeptin-10 | 13 healthy adult men | Effect of a single intravenous bolus on the timing and size of LH pulses | Induced an immediate LH pulse larger than endogenous pulses (amplitude 5.0 versus 2.1 mIU/mL, P = .02) and reset the GnRH pulse generator | Single intravenous bolus, healthy men | 21470997 |
| Kisspeptin-10 | 5 hypotestosteronaemic men with type 2 diabetes and 7 age-matched healthy men | LH and testosterone response to a bolus and an 11-hour infusion | In the diabetic men testosterone rose from 8.5 to 11.4 nmol/L (P = .002), alongside a rise in LH from 3.9 to 20.7 IU/L and in LH pulse frequency from 0.6 to 0.9 pulses per hour | Proof-of-concept study, intravenous bolus and infusion | 23153270 |
| Gonadorelin (pulsatile GnRH pump) | 54 adult men with congenital hypogonadotropic hypogonadism | Serum testosterone, testicular volume and sperm output before and at 6, 12 and 24 months | Mean testosterone rose from 48 to 381 ng/dL by 24 months (P below .01); 27 of 45 followed men produced spermatozoa | Retrospective cohort, subcutaneous pulsatile pump | 40800099 |
| Enclomiphene citrate (a SERM, not a peptide; comparator) | Men with secondary hypogonadism (n not stated in the abstract) | LH, FSH, testosterone and semen analysis versus topical testosterone gel | Morning testosterone rose to levels similar to topical testosterone gel while LH and FSH rose and sperm counts were conserved | Randomised phase II trial, oral versus topical | 25044085 |
| Clomiphene citrate (a SERM, not a peptide; comparator) | 15 men with secondary hypogonadism on daily clomiphene for a median 25.9 months | Total testosterone before and during treatment | Median total testosterone rose from 205 to 488 ng/dL | Prospective observational cohort | 27511863 |
Kisspeptin Trials
Kisspeptin sits at the top of the axis, driving the hypothalamus to release GnRH. In an early human male study, a double-blind placebo-controlled crossover, 6 volunteers given a 90-minute kisspeptin-54 infusion saw plasma LH, FSH and testosterone rise against saline, with 180-minute testosterone 24.9 versus 21.7 nmol/L (PMID 16174713). A dose-response study of kisspeptin-10 in healthy men then showed LH climbing from 5.4 to 20.8 IU/L and testosterone from 16.6 to 24.0 nmol/L, alongside a rise in LH pulse frequency (PMID 21632807). A separate bolus study in 13 men found kisspeptin-10 could reset the timing of the GnRH pulse generator (PMID 21470997). Background on the molecule sits on the kisspeptin page.
One study moved from healthy physiology toward a clinical population. In 5 hypotestosteronaemic men with type 2 diabetes, a kisspeptin-10 infusion raised LH from 3.9 to 20.7 IU/L and testosterone from 8.5 to 11.4 nmol/L (PMID 23153270), a proof-of-concept result in men with central hypogonadism rather than a treatment trial. What testosterone is and how it is measured sits on the testosterone guide, and the demographic questions men ask sit on the peptides for men guide.
GnRH And The Pump
Gonadorelin is GnRH itself, the pituitary signal one step below kisspeptin. Delivered in pulses by a subcutaneous pump it mimics the natural hypothalamic rhythm. In a retrospective cohort of 54 adult men with congenital hypogonadotropic hypogonadism, a pulsatile GnRH pump raised mean serum testosterone from 48 to 381 ng/dL over 24 months while testicular volume grew and 27 of 45 followed men produced spermatozoa (PMID 40800099). This is a treatment-intent study in men with a diagnosed condition, so the result belongs to that population and is managed by a clinician. How the axis and its hormones fit together sits on the hormones guide.
The SERM Comparators
Enclomiphene and clomiphene are selective estrogen receptor modulators, small molecules rather than peptides, included because they raise endogenous testosterone through the same axis by lifting LH and FSH. In a randomised phase II trial in men with secondary hypogonadism, oral enclomiphene raised morning testosterone to levels similar to a topical testosterone gel while LH and FSH rose and sperm counts were conserved (PMID 25044085). In a prospective cohort of 15 men on long-term daily clomiphene for a median of about 26 months, median total testosterone rose from 205 to 488 ng/dL (PMID 27511863). In the US, clomiphene is not FDA-approved for men and is used off label for this purpose (PMID 27337642). These raise the body’s own output rather than supplying testosterone from outside, which is the distinction the TRT guide covers. The compound-level detail sits on the enclomiphene guide.
The Trial Regimens
The regimens those trials administered, each named with its paper:
Kisspeptin-54 as a 90-minute intravenous infusion in the healthy-male crossover (PMID 16174713). Kisspeptin-10 as intravenous boluses of 0.01 to 3.0 micrograms per kg and infusions of 1.5 to 4 micrograms per kg per hour in the healthy-male dose-response study (PMID 21632807). Clomiphene citrate 25 mg by mouth daily in the secondary-hypogonadism cohort (PMID 27511863). Enclomiphene citrate by mouth compared against a 1 percent topical testosterone gel in the phase II trial (PMID 25044085).
Disclaimer: these are trial arms reported for comparison, not recommendations and not a titration schedule. Each was administered under medical supervision inside its study, and the intravenous and pump regimens in particular are clinical procedures. What to check before buying anything sits on the COA verification guide.
How These Records Were Found
Each line states a query, an index and a date. A search result describes what a string matched in one database on one day, nothing beyond that.
- kisspeptin AND testosterone AND men in PubMed on 9 August 2026 returned 39 records, among them PMID 21632807 and PMID 23153270.
- kisspeptin AND luteinizing hormone AND men in PubMed on 9 August 2026 returned 43 records.
- kisspeptin-54 AND hypothalamic-pituitary-gonadal AND males in PubMed on 9 August 2026 returned 36 records; the 2005 crossover read here is PMID 16174713.
- The author search George JT kisspeptin men in PubMed on 9 August 2026 returned 6 records, and a Chan kisspeptin men search returned 8, among them PMID 21470997.
- enclomiphene AND testosterone in PubMed on 9 August 2026 returned 29 records; the randomised phase II trial retrieved was PMID 25044085.
- clomiphene citrate AND hypogonadism AND testosterone AND randomized in PubMed on 9 August 2026 returned 25 records; the cohort read here is PMID 27511863.
- pulsatile GnRH AND congenital hypogonadotropic hypogonadism AND testosterone in PubMed on 9 August 2026 returned 39 records, among them PMID 40800099.
- A compound name bounds a search, so synonyms and MeSH entry terms were tried: kisspeptin as kisspeptin-54, kisspeptin-10 and metastin; GnRH as gonadorelin and gonadotropin-releasing hormone; enclomiphene as the trans isomer of clomiphene.
Frequently Asked Questions
What are the best peptides for testosterone?+
This page does not rank them. It reports what each cited trial enrolled, what it measured and what it found, so a 90-minute infusion in 6 healthy volunteers (PMID 16174713) and a 2-year pump cohort in 54 men with congenital hypogonadotropic hypogonadism (PMID 40800099) can be told apart. Low testosterone is a medical condition, and the population column is where each result is pinned to the people the trial enrolled.
Is low testosterone something to treat on your own?+
No. Low testosterone, or hypogonadism, is diagnosed and managed with a clinician, because the cause changes the plan and some causes are serious. Every regimen in the table above was administered inside a study under medical supervision. Take a measured testosterone level and its likely cause to a doctor, not a compound name off a label.
How is signalling the axis different from testosterone replacement?+
The compounds in the table act upstream on the hypothalamic-pituitary-gonadal axis. Kisspeptin drives GnRH release, gonadorelin is GnRH itself delivered in pulses, and the SERMs raise the body’s own LH and FSH, so testosterone rises from the testes (PMID 21632807, PMID 40800099). Replacement supplies testosterone from outside the body and tends to lower LH instead. The trade-offs of replacement sit on the TRT guide.
Are enclomiphene and clomiphene peptides?+
No. Enclomiphene and clomiphene are selective estrogen receptor modulators, small molecules rather than peptides. They appear here as comparators because they raise endogenous testosterone through the same axis. In the phase II trial enclomiphene raised morning testosterone to levels similar to a topical testosterone gel (PMID 25044085), and a clomiphene cohort saw median total testosterone rise from 205 to 488 ng/dL (PMID 27511863).
What did the kisspeptin studies actually measure?+
They measured hormones over minutes to hours, not months. The kisspeptin-54 crossover tracked plasma LH, FSH and testosterone during a 90-minute infusion (PMID 16174713). The kisspeptin-10 work tracked LH, LH pulse frequency and testosterone during boluses and infusions (PMID 21632807), and one bolus study tracked how a single dose reset the timing of LH pulses (PMID 21470997). These are physiology studies of the axis, not long-term treatment trials.
Do these results apply to a healthy man who just wants higher testosterone?+
Read the population and the design first. Several kisspeptin studies enrolled healthy male volunteers for short physiology experiments (PMID 16174713, PMID 21470997), while the pump cohort and the diabetes study enrolled men with a diagnosed condition (PMID 40800099, PMID 23153270). A short-term hormone rise in a physiology study is not evidence of a long-term benefit in a healthy man, and that question was not an endpoint in these studies.
What is gonadorelin?+
Gonadorelin is gonadotropin-releasing hormone, the hypothalamic signal that tells the pituitary to release LH and FSH. Delivered in pulses by a pump it mimics the natural rhythm, and in 54 men with congenital hypogonadotropic hypogonadism a pulsatile pump raised mean testosterone from 48 to 381 ng/dL over 24 months (PMID 40800099). Background on the axis and its hormones sits on the hormones guide.
Research And Sources
Every figure above comes from the record its PMID links to, retrieved through NCBI E-utilities on 9 August 2026. The kisspeptin-54 testosterone and LH figures come from PMID 16174713, the kisspeptin-10 dose-response figures from PMID 21632807, the diabetes proof-of-concept figures from PMID 23153270, the pulsatile GnRH testosterone rise from PMID 40800099, and the clomiphene cohort figures from PMID 27511863. The provenance section records what each search returned rather than the body claiming anything about what does or does not exist.
Related Reading
For education only, not medical advice. Low testosterone is a medical condition, and every dose figure here is a trial figure reported for comparison, not a recommendation. Every regimen above was administered under medical supervision inside its trial. Diagnosis and treatment of hypogonadism are managed by a clinician. Talk to a doctor before starting, stopping or changing anything.